Bipolar Disorder
Some studies have suggested a significant correlation between creativity and bipolar disorder. However, the relationship between the disorder and creativity is still very unclear.[3][4][5] One study indicated increased striving for, and sometimes attaining, goals and achievements.[6] While the disorder affects people differently, individuals with bipolar disorder tend to be much more outgoing and daring than individuals without bipolar disorder. The disorder is also found in a large number of people involved in the arts. It is an ongoing study as to why many creative geniuses had bipolar disorder.
http://en.wikipedia.org/wiki/Bipolar_disorder
Depakine® (sodium valproate)
logo depakine
Depakine® is a broad-spectrum anti-convulsant. Prescribed for more than 38 years, it remains a first-treatment choice for epilepsy worldwide.
Sodium valproate is available in a large variety of formulations (syrups, soluble drinks, injections, gastro-resistant tablets and Chrono®, an extended-release tablet) in order to cover the full range of patient needs.
Depakine® Chronosphere®, a new sustained-release sachet formulation, has been approved in several European countries. It was launched in Austria in October 2004 and in France and Germany in 2005. This new formulation is easier to use for children (it was the first extended release pediatric form of Depakine®) and for the elderly or adults who have difficulty swallowing. Product launches are planned in most European countries.
Sanofi-aventis has also demonstrated the role this medicine can play in bipolar disorders* which affect approximately 2% of the world’s population and are characterized by alternate manic and depressive episodes. In 2005, Depakine® Chrono® and Chronosphere® were approved for this indication in several European countries.
Sodium valproate is marketed in over 100 countries.
http://en.sanofi-aventis.com/group/products/p_group_products_nervous_depakine.asp
Valproate is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain, making it an alternative to lithium salts in treatment of bipolar disorder. However, several other mechanisms of action in neuropsychiatric disorders have been proposed for valproic acid in recent years.[1]. It also blocks voltage-gated sodium channels.
Valproic acid is an inhibitor of the enzyme histone deacetylase 1 (HDAC1). It is a member of a larger class of histone deacetylase inhibitors that have a broad spectrum of epigenetic activities.
http://en.wikipedia.org/wiki/Valproic_acid
Alzen
Antipsicótico de 2ª geração
http://www.min-saude.pt/Portal/servicos/prontuario/detalhe/?medicineID=29542
Quetiapina
http://pt.wikipedia.org/wiki/Quetiapina
Esses novos medicamentos tem se mostrado um novo e valioso recurso terapêutico nas psicoses, principalmente naquelas refratárias aos antipsicóticos tradicionais, nos casos de intolerância aos efeitos colaterais extra piramidais, bem como nas psicoses predominantemente com sintomas negativos, onde os antipsicóticos tradicionais podem ser ineficazes.
De forma ampla os Antipsicóticos Atípicos são definidos como uma nova classe desses medicamentos que causam menos efeitos colaterais extra-piramidais, ao menos em doses terapêuticas. Eles são os seguintes:
AMISULPRIDA Socian
CLOZAPINA Leponex
OLANZAPINA Zyprexa
QUETIAPINA Seroquel
RISPERIDONA Risperdal Zargus
ZUCLOPENTIXOL Clopixol (em breve)
ZIPRASIDONA Geodon
http://virtualpsy.locaweb.com.br/index.php?art=281&sec=61
Socian
http://foruns.terravista.pt/SForums/$M=readthreadrep$TH=2032234$F=45094$ME=5956224
Venlafaxina
http://pt.wikipedia.org/wiki/Venlafaxina
Amineptine
Survector
http://en.wikipedia.org/wiki/Amineptine
http://en.wikipedia.org/wiki/Bipolar_disorder
Depakine® (sodium valproate)
logo depakine
Depakine® is a broad-spectrum anti-convulsant. Prescribed for more than 38 years, it remains a first-treatment choice for epilepsy worldwide.
Sodium valproate is available in a large variety of formulations (syrups, soluble drinks, injections, gastro-resistant tablets and Chrono®, an extended-release tablet) in order to cover the full range of patient needs.
Depakine® Chronosphere®, a new sustained-release sachet formulation, has been approved in several European countries. It was launched in Austria in October 2004 and in France and Germany in 2005. This new formulation is easier to use for children (it was the first extended release pediatric form of Depakine®) and for the elderly or adults who have difficulty swallowing. Product launches are planned in most European countries.
Sanofi-aventis has also demonstrated the role this medicine can play in bipolar disorders* which affect approximately 2% of the world’s population and are characterized by alternate manic and depressive episodes. In 2005, Depakine® Chrono® and Chronosphere® were approved for this indication in several European countries.
Sodium valproate is marketed in over 100 countries.
http://en.sanofi-aventis.com/group/products/p_group_products_nervous_depakine.asp
Valproate is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain, making it an alternative to lithium salts in treatment of bipolar disorder. However, several other mechanisms of action in neuropsychiatric disorders have been proposed for valproic acid in recent years.[1]. It also blocks voltage-gated sodium channels.
Valproic acid is an inhibitor of the enzyme histone deacetylase 1 (HDAC1). It is a member of a larger class of histone deacetylase inhibitors that have a broad spectrum of epigenetic activities.
http://en.wikipedia.org/wiki/Valproic_acid
Alzen
Antipsicótico de 2ª geração
http://www.min-saude.pt/Portal/servicos/prontuario/detalhe/?medicineID=29542
Quetiapina
http://pt.wikipedia.org/wiki/Quetiapina
Esses novos medicamentos tem se mostrado um novo e valioso recurso terapêutico nas psicoses, principalmente naquelas refratárias aos antipsicóticos tradicionais, nos casos de intolerância aos efeitos colaterais extra piramidais, bem como nas psicoses predominantemente com sintomas negativos, onde os antipsicóticos tradicionais podem ser ineficazes.
De forma ampla os Antipsicóticos Atípicos são definidos como uma nova classe desses medicamentos que causam menos efeitos colaterais extra-piramidais, ao menos em doses terapêuticas. Eles são os seguintes:
AMISULPRIDA Socian
CLOZAPINA Leponex
OLANZAPINA Zyprexa
QUETIAPINA Seroquel
RISPERIDONA Risperdal Zargus
ZUCLOPENTIXOL Clopixol (em breve)
ZIPRASIDONA Geodon
http://virtualpsy.locaweb.com.br/index.php?art=281&sec=61
Socian
http://foruns.terravista.pt/SForums/$M=readthreadrep$TH=2032234$F=45094$ME=5956224
Venlafaxina
http://pt.wikipedia.org/wiki/Venlafaxina
Amineptine
Survector
http://en.wikipedia.org/wiki/Amineptine
Comments